SecBot SecBot
8-K ·Filed Nov 5, 2026

LGVN

Longeveron Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed11d 10h ago SEC0001213900-26-116360
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any subsequent filing naming a replacement director or any unusual board activity. A single director resignation for health reasons is routine and does not signal operational issues.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.81
T+0 close · Nov 5, 2026 · via day close
Latest settled
+37.57%
T+5 · $2.49 · next T+20 in 20d
Vs SPY
+34.97%
α at T+5
Latest observation
+25.58%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $1.81entry
  2. T+1 · 8d ago +11.05%α +8.68% · $2.01
  3. T+5 · 4d ago +37.57%α +34.97% · $2.49
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Board member Ursula Ungaro resigned immediately from Longeveron's Board and all committees on November 1, 2026, citing personal health issues. The filing states the resignation was not due to any disagreement with the company. No replacement has been named.

Key Facts

  • Ursula Ungaro resigned from the Board of Directors effective November 1, 2026
  • Resignation also covers Audit, Compensation, Nominating and Corporate Governance, and Special Committees
  • Reason given: personal health issues, not a disagreement with the company
  • No replacement named in the filing

Financial Impact

No financial impact stated; a single board resignation with no stated disagreement

Risk Factors

  • Loss of board diversity or specific expertise if not replaced promptly
  • Potential for additional departures if underlying governance issues exist, though none are indicated

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-116360
Document: 0001213900-26-116360-index-headers.html0001213900-26-116360
Document: 0001213900-26-116360-index.html0001213900-26-116360
Document: 0001213900-26-116360.txt0001213900-26-116360

Track record

22 reports on LGVN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
  3. Nov 12, 20264d ago 8-K Bearish 7/10 No price data
  4. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
  5. Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
  6. Nov 5, 202611d ago 8-K Neutral 2/10 Viewing Entry $1.81 Now $2.14 +18.23% settles Feb 4
  7. Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
  8. Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
  9. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
  10. Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026